After IPO, BridgeBio Looks To Tuck Eidos Back Into Its Flock

 
• By Mandy Jackson
  
Eggs_Nest
In case Eidos's ATTR drug AG10 is a golden egg, BridgeBio wants to own it all. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business